Evidence map›Paper›PMID 27608486›Full record

ArticleeLife2016

Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth.

Romi Gupta, Matteo Forloni, Malik Bisserier, Shaillay Kumar Dogra, Qiaohong Yang, Narendra Wajapeyee

Open access · goldAbstract read
In one paragraph

Article in eLife, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  16. Mechanisms of IFNalpha-1a-Induced Apoptosis in a Laryngeal Cancer Cell Line.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Romi GuptaDepartment of Pathology, Yale University School of Medicine, New Haven, United States.
Matteo ForloniDepartment of Pathology, Yale University School of Medicine, New Haven, United States.
Malik BisserierDepartment of Pathology, Yale University School of Medicine, New Haven, United States.
Shaillay Kumar DograSingapore Institute of Clinical Sciences, Agency for Science Technology and Research (A*STAR), Brenner Center for Molecular Medicine, Singapore, Singapore.
Qiaohong YangDepartment of Pathology, Yale University School of Medicine, New Haven, United States.
Narendra WajapeyeeDepartment of Pathology, Yale University School of Medicine, New Haven, United States.ORCID http://orcid.org/0000-0003-3306-349X
Yale University · USAgency for Science, Technology and Research · SG

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMAR01CA200919 · NCI · YALE UNIVERSITY · PI WAJAPEYEE, NARENDRA · 2016 to 2020
$1.8M
Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and MetastasisR01CA196566 · NCI · YALE UNIVERSITY · PI WAJAPEYEE, NARENDRA · 2016 to 2020
$1.8M
Metabolic Drivers of Melanoma Initiation, Progression and Therapy ResponseR21CA191364 · NCI · YALE UNIVERSITY · PI WAJAPEYEE, NARENDRA · 2015 to 2016
$398k
METABOLIC DRIVERS OF LUNG CANCER INITIATION, PROGRESSION AND THERAPY RESPONSER21CA197758 · NCI · YALE UNIVERSITY · PI WAJAPEYEE, NARENDRA · 2015 to 2016
$398k
ANOIKIS EFFECTORS AS DRIVERS OF METASTATIC MELANOMAR21CA195077 · NCI · YALE UNIVERSITY · PI WAJAPEYEE, NARENDRA · 2016 to 2016
$218k
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA196566NCI NIH HHS R01 CA200919NCI NIH HHS R21 CA191364NCI NIH HHS R21 CA195077NCI NIH HHS R21 CA197758
6 · The paper itself

Abstract

Mutations in the

Indexed as

cancer biologyDNA replicationhumanmelanomaRAS

Identifiers

PMID27608486
PMCPMC5031487
OpenAlexW2517031580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.